InflaRx Banks $150 Million to Fund Kidney Disease Pivot After COVID Drug Retreat
Veröffentlicht: 07.05.2026 um 18:51 Uhr, Redaktion boerse-global.de
The Jena-based biotech has pulled off a dramatic strategic overhaul, abandoning active promotion of its COVID-19 therapy to pour resources into a promising oral candidate for rare kidney conditions. A freshly completed capital raise gives the company breathing room through 2029.
InflaRx placed 75 million new shares at $2.00 apiece, generating gross proceeds of roughly $150 million. Institutional heavyweights including Farallon Capital and TCGX backed the offering. The cash injection transforms the company's financial runway, with management now projecting sufficient liquidity to fund operations until the end of the decade.
The first-quarter results already reflect the cost-cutting drive. Net loss narrowed to €5.6 million from €8.3 million in the same period last year, while operating expenses dropped to €7.5 million. Headcount reductions and renegotiated service contracts drove the improvement. The company ended March with approximately €39.7 million in cash on hand.
Should investors sell immediately? Or is it worth buying InflaRx?
The strategic reset centers on pulling the plug on active U.S. marketing for Gohibic, the company's COVID-19 treatment. The drug remains available under its existing emergency authorization, but the sales and promotional infrastructure is being dismantled. Those freed-up resources are now flowing entirely into Izicopan, an oral C5a receptor inhibitor.
InflaRx is targeting ANCA-associated vasculitis as the lead indication, with a Phase 2 study currently in the planning stages. Additional indications such as atypical hemolytic uremic syndrome are also on the drawing board. First clinical data from the kidney programs are expected next year. A bridging study in China is slated for later in 2025.
Wall Street analysts have largely welcomed the repositioning. The consensus rating leans bullish, with an average price target of $5.80. Management plans to lay out the full strategic blueprint during a webcast on May 8, followed by a capital markets day in summer 2026.
Despite the strengthened balance sheet, the company's financial report carries the standard going-concern language common among loss-making biotech firms. That caveat aside, the funding cushion buys InflaRx the time needed to advance Izicopan through key clinical milestones without the constant pressure of near-term capital needs.
Ad
InflaRx Stock: New Analysis - 7 May
Fresh InflaRx information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
